SHOC2 ablation sensitised all KRAS- and EGFR-mutant NSCLC cell lines tested, except one (H727), to the MEK inhibitors Selumetinib (Fig. 3b, c, Supplementary Fig. 4a, c) and Trametinib (Fig. 3c, Supplementary Fig. 3c), but had no effect on the response of BRAF-mutant or WT cell lines. The gene discussed is SHOC2; the disease is non-small cell lung carcinoma.